Mice immunized with Ad35.HSV.gB2 alone showed 67% survival after challenge and the clinical score of surviving animals remained on average between 1 (genital edema and erythema) and 3 (purulent genital lesions or ulcers) during the 21 days of disease monitoring. This evidence concerns the gene GABBR2 and Erythema.